LC
ABBV icon

Legacy CG’s AbbVie ABBV Stock Holding History

Legacy CG’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.07M Buy
27,903
+256
+0.9% +$56.8K 1.69% 24
2025
Q4 		$6.32M Sell
27,647
-191
-0.7% -$43.5K 1.77% 22
2025
Q3 		$6.45M Buy
27,838
+14,257
+105% +$2.9M 1.82% 25
2025
Q2 		$2.52M Buy
+13,581
New +$2.52M 0.75% 43

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Legacy CG's ABBV Position: Q1 2026 in Review

Legacy CG increased its AbbVie (ABBV) stake by 0.93% in Q1 2026, buying an estimated $56.8K and bringing the position to 27,903 shares worth $6.07M. The position accounts for 1.69% of the portfolio, ranked #24.

Legacy CG first reported a position in ABBV in Q2 2025 and has held it in 4 quarters since. The position peaked at $6.45M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Legacy CG held 27,903 shares of AbbVie worth $6.07M as of Q1 2026.
  • Legacy CG bought 256 AbbVie shares in Q1 2026, an estimated $56.8K.
  • AbbVie made up 1.69% of Legacy CG's portfolio in Q1 2026, its #24 holding.
  • Legacy CG first reported a position in AbbVie in Q2 2025 and has held it in 4 quarters since.
  • Legacy CG's AbbVie position peaked at $6.45M in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Legacy CG's 13F filing for Q1 2026, filed 5 May 2026.